scholarly journals Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents

2007 ◽  
Vol 15 (11) ◽  
pp. 382-386 ◽  
Author(s):  
F. H. de Man ◽  
P. R. Stella ◽  
H. Nathoe ◽  
H. Kirkels ◽  
B. Hamer ◽  
...  
Keyword(s):  
Stent Thrombosis ◽  
Real World ◽  
Bare Metal Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Drug Eluting

Abstract 20233: Does Evidence Influence Practice in the Real World? Secular Trends in Indication for PCI and Use of Drug-Eluting vs. Bare-Metal Stents From 2006-2012

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Elizabeth B Pathak ◽  
Jason L Salemi ◽  
Amit P Pathak
Keyword(s):  
Real World ◽  
Bare Metal Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Discharge Data ◽  
The Real ◽  
Primary Indication ◽  
Stable Coronary Heart Disease ◽  
Before And After ◽  
Drug Eluting

Introduction: In this study, we examined the real-world impact of research evidence on the use of and indications for percutaneous coronary intervention (PCI) (before and after COURAGE Trial publication) and the choice of drug eluting stents (DES) vs. bare metal stents (BMS) (before and after FDA warnings about risk of DES thrombosis). Methods: We used hospital discharge data from Florida to calculate the distribution of primary indication for PCI and the % of PCI patients who received DES, BMS, or no stent on a quarterly basis from Jan 2006 - Jun 2012. We plotted stent trends separately for patients with principal diagnosis of STEMI (n=66,054), NSTEMI/ICS (n=140,886), and stable CHD (n=117,307). Results: Since 2006, the % of PCIs with a primary indication of either STEMI or NSTEMI has steadily increased, while the % with an indication of stable CHD declined from 45% to 28%. In early 2006, DES were used in 86.9% of NSTEMI patients, 87.5% of stable CHD patients, and 81.4% of STEMI patients. DES use first declined in all diagnosis groups in Q3 2006, coinciding with the release of meta-analysis results showing higher risk of late stent thrombosis for DES vs. BMS. The lowest rate of DES usage was reached in Q1 2008 (45% for STEMI, 63% for NSTEMI, 67% for stable CHD). However, by Q2 2012, DES use had increased to 60% in STEMI cases, 75% in NSTEMI cases, and 76% in stable CHD cases. The percent of PCI patients who received no stent has remained stable at < 9% since 2006, regardless of diagnosis. Conclusions: The COURAGE Trial showed no benefit of PCI over medical treatment in stable coronary heart disease (CHD). From 2006-2012, the proportion of PCIs with an indication of stable CHD declined from 45% to 28%, indicating a real-world response to evidence. Similarly, following controversy about long-term effects of DES, off-label use, and patient compliance with thienopyridines which began in late 2006, there was an immediate resurgence in use of BMS, especially for STEMI. However, the proportion of patients receiving DES has steadily increased since early 2008, regardless of primary indication. More research on the influence of provider and hospital characteristics on response to evidence is needed.

scholarly journals Characteristics and prognosis of patients with angiographic stent thrombosis: comparison between drug-eluting and bare-metal stents

2008 ◽  
Vol 101 (4) ◽  
pp. 220-225 ◽  
Author(s):  
C. Le Feuvre ◽  
G. Helft ◽  
S. Cohen ◽  
J.-P. Batisse ◽  
O. Barthélémy ◽  
...  
Keyword(s):  
Stent Thrombosis ◽  
Bare Metal Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Drug Eluting

scholarly journals CE4 COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA

2006 ◽  
Vol 9 (3) ◽  
pp. A8
Author(s):  
G Blackhouse ◽  
J Bowen ◽  
JE Tarride ◽  
R Hopkins ◽  
D O'Reilly ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Real World ◽  
Bare Metal Stents ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Real World Data ◽  
World Data ◽  
Drug Eluting

Results in Complex Multivessel and Multilesion PCI in Patients Treated with a Combination of Drug Eluting Stents and Bare Metal Stents in Real World Practice

2008 ◽  
Vol 17 ◽  
pp. S163
Author(s):  
Ravinder Batra ◽  
Akshay Mishra ◽  
Rohan Jayasinghe ◽  
Sharmalar Rajendran ◽  
Naylin Bissessor ◽  
...  
Keyword(s):  
Real World ◽  
Bare Metal Stents ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Drug Eluting

Stent Thrombosis

2017 ◽  
Vol 44 (01) ◽  
pp. 046-051 ◽  
Author(s):  
Mukesh Gopalakrishnan ◽  
Amir Lotfi
Keyword(s):  
Stent Thrombosis ◽  
Detrimental Effect ◽  
Bare Metal Stents ◽  
Coronary Intervention ◽  
Drug Eluting Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Percutaneous Coronary ◽  
Drug Eluting ◽  
Significant Detrimental Effect

AbstractThe most dreaded complication with percutaneous coronary intervention with stents, either bare-metal or drug-eluting stents is stent thrombosis (ST) and it has a significant detrimental effect on the outcome for the patient. The initial attempts at intervention with bare-metal stents had much higher rates of ST compared with what is currently prevailing in the modern interventional world. Significant changes with respect to the stent technology, pharmacology, and most importantly our understanding of this phenomenon have decreased the risk of ST. There are many factors that can be performed to minimize the risk of ST and this review will describe the incidence, pathophysiology, and contributing risk factors to ST.

Sign in / Sign up

Export Citation Format

Share Document